Grace Therapeutics (GRCE) 10% Owner Inc. Buys $69K of Stock

Opaleye Management Inc. purchased 36,347 shares of Grace Therapeutics, Inc. (GRCE) on October 16, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the shares were acquired at a price of $1.89 each for a total value of $68,757.62.

Inside Opaleye Management's Grace Therapeutics Trade

The 10% owner grew its holdings by 36,347 shares in this transaction, marking a 1.25% increase in its total stake. Following the purchase, the entity held 2,944,354 shares of the biotechnology company. This latest buy follows four earlier purchases by the firm recorded between October 5 and October 12, 2026, continuing a string of steady acquisitions in the company.

Other Institutional Activity in Grace Therapeutics

Other institutional investors have also adjusted their positions in Grace Therapeutics recently. Eversept Partners, LP grew its holdings by 16,268 shares, ending with 772,900 shares worth about $1,460,780. Citadel Advisors Llc grew its holdings by 250,999 shares, ending with 349,740 shares worth about $661,008. Maven Securities Limited grew its holdings by 100,000 shares, ending with 200,000 shares worth about $377,999. Birchview Capital, LP grew its holdings by 70,000 shares, ending with 120,000 shares worth about $226,799. Cerity Partners LLC kept its holdings unchanged at 849,055 shares worth about $1,604,713.

Grace Therapeutics, Inc. Stock Down 3.1%

Grace Therapeutics shares recently traded around $1.89, sitting 10.9% below their 50-day moving average of $2.12 and 35.1% below their 200-day moving average of $2.91. The stock trades 5.6% above its 52-week low of $1.79 and 63.5% below its 52-week high of $5.18. The company has a market capitalization of $39.8 million.

Recent Earnings

The company reported trailing twelve-month earnings per share of -$1.17, reflecting that it is not yet profitable. It carries a trailing net margin of 0.0% and a return on equity of -36.2%.

Insider Buying and Selling at Grace Therapeutics, Inc.

Insiders have been active in the stock recently, with Opaleye Management making several prior purchases in October 2026. These included a buy of 60,490 shares on October 5, a purchase of 5,340 shares on October 9 at $2.04 per share, a pickup of 7,215 shares on October 12 at $2.02 per share, and another acquisition of 14,632 shares on October 12.

About Grace Therapeutics

Grace Therapeutics, Inc. is a Princeton, New Jersey-based biotechnology company with a team of five employees. The firm focuses on developing and commercializing pharmaceutical treatments for rare and orphan diseases in Canada. Its primary product candidate is GTX-104, an injectable formulation designed to treat aneurysmal subarachnoid hemorrhage. Ongoing regulatory and clinical milestones for this lead asset remain a primary focus for long-term stakeholders.

Bottom Line

Opaleye Management's continued accumulation of shares highlights steady interest from its largest backers. Observers will watch for future SEC filings to see if the firm extends its buying streak.